Akorn Recalls Lidocaine and Prilocaine Cream Due to Impurity
Akorn, Inc. is recalling Lidocaine 2.5% and Prilocaine Cream because routine stability testing found an unknown impurity.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' severity score under the rubric, as it involves a product that may cause temporary or medically reversible adverse health consequences.
Plain-English summary
Akorn, Inc. is recalling Lidocaine 2.5% and Prilocaine Cream, 2.5%, 30g tubes. The product is prescription-only and was manufactured by Hi-Tech Pharmacal Co., Inc. in Amityville, NY. The recall involves 22,605 tubes with Lot # 356309 and an expiration date of 3/2019. The product was distributed nationwide within the USA.
The recall was initiated because out-of-specification results for an unknown impurity were found during routine stability testing at 12 months. This is classified as an FDA Class II recall.
Consumers and healthcare providers should stop using the affected product and contact their pharmacist or healthcare provider for guidance on replacement or disposal.
The recalled product
- Product
- Lidocaine 2.5% and Prilocaine Cream, 2.5%. 30g tube, Rx only, Manufactured by: Hi-Tech Pharmacal Co., Inc., Amityville, NY 11701, NDC 50383-667-30
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Topical Anesthetic
- Hazard
- Affected units
- 22,605
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 356309
- Exp. 3/2019
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- ModerateLidocaine-Prilocaine Cream Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- ModerateAkorn Lidocaine Oral Solution Recalled Due to Manufacturing Compliance Deviations
FDA (Drugs) · 2023-06-07
- ModerateLidocaine Ointment USP Recalled Due to Manufacturing Process Deviations
FDA (Drugs) · 2023-06-07
- ModerateLidocaine Oral Topical Solution Recalled Due to Failed Viscosity Specification
FDA (Drugs) · 2022-05-11
- ModerateAkorn Recalls Lidocaine Hydrochloride Jelly Due to Metal Particulate Finding
FDA (Drugs) · 2019-10-02
- HighLidocaine HCl Jelly 2% recalled nationwide for manufacturing compliance deviations
FDA (Drugs) · 2023-06-07